Notably, within the chemical library, compound 32 works as a partial antagonist, whereas compound 35 is a potent pure antagonist that provokes protein polyubiquitination, ERα downregulation and cell cycle arrest of ER+ BC cells. The gene discussed is ERAL1; the disease is breast cancer.